Myovant Sciences Ltd. (MYOV)
NYSE: MYOV
· Real-Time Price · USD
26.98
-0.01 (-0.04%)
At close: Mar 09, 2023, 10:01 PM
Myovant Sciences Balance Sheet Statement
Financials in USD. Fiscal
year is
April - March.
| Fiscal Year | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 |
Cash & Equivalents | 250.59M | 341.96M | 325.54M | 406.7M | 457.74M | 518.16M | 484.96M | 674.49M | 713.52M | 94.21M | 84.73M |
Short-Term Investments | 23.85M | 29.33M | 31.22M | 27.48M | 70.02M | 97.85M | 84.83M | 10.44M | 32.32M | 17.09M | 14.97M |
Long-Term Investments | n/a | n/a | 1.94M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 7.29M | 13.33M | 21.18M | 20.96M | 18.18M | 12.74M | 13.41M | 7.43M | 7.29M | 5.63M | 4.37M |
Receivables | 41.02M | 33.76M | 29.65M | 23.3M | 18.91M | 14.4M | 10.61M | 3.57M | n/a | n/a | n/a |
Inventory | 30.08M | 23.05M | 21.22M | 7.58M | 6.74M | 6.14M | 4.17M | 2.61M | n/a | n/a | n/a |
Other Current Assets | 41.04M | 32.81M | 19.21M | 23.08M | 21.34M | 18.11M | 117.57M | 13.54M | 8.18M | 5.61M | 9.37M |
Total Current Assets | 386.59M | 460.91M | 426.83M | 488.14M | 574.75M | 654.67M | 702.13M | 704.64M | 754.03M | 116.91M | 109.07M |
Property-Plant & Equipment | 9.64M | 9.73M | 10.18M | 10.9M | 11.36M | 12.13M | 12.22M | 12.96M | 12.89M | 13.23M | 13.24M |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 16.93M | 23.06M | 33.3M | 31.87M | 29.54M | 24.87M | 25.64M | 20.38M | 20.19M | 18.86M | 17.62M |
Total Assets | 403.52M | 483.97M | 460.13M | 520.01M | 604.29M | 679.54M | 727.77M | 725.03M | 774.21M | 135.77M | 126.68M |
Account Payables | 12.22M | 8.21M | 9.55M | 12.25M | 12.13M | 8.64M | 9.12M | 17.81M | 12.36M | 7.01M | 5.39M |
Deferred Revenue | 117.23M | 117.85M | 109.12M | 135.21M | 155.59M | 185.33M | 221.41M | 193.14M | 192.98M | 16.67M | 16.67M |
Short-Term Debt | 2.7M | 2.37M | 2.26M | 2.15M | 2.05M | 1.97M | 1.89M | 1.81M | 1.73M | 1.66M | 1.58M |
Other Current Liabilities | 113.6M | 123.87M | 113.87M | 135.37M | 154.29M | 157.16M | 179.33M | 161.16M | 137.42M | 41.42M | 28.94M |
Total Current Liabilities | 245.75M | 251.69M | 226.24M | 250.33M | 269.04M | 268.34M | 307.57M | 281.34M | 252.07M | 66.76M | 52.58M |
Long-Term Debt | 364.18M | 364.49M | 365.13M | 365.74M | 366.32M | 366.86M | 367.38M | 367.89M | 323.37M | 263.83M | 204.27M |
Other Long-Term Liabilities | 1.72M | 1.72M | 1.72M | 1.71M | 371K | 1.25M | 1.25M | 32.39M | 51.09M | 4.97M | 4.44M |
Total Long-Term Liabilities | 715.91M | 745.53M | 717.41M | 743.16M | 767.54M | 794.13M | 819.83M | 797.65M | 792.8M | 268.8M | 208.71M |
Total Liabilities | 961.66M | 997.22M | 943.65M | 993.49M | 1.04B | 1.06B | 1.13B | 1.08B | 1.04B | 335.55M | 261.29M |
Total Debt | 366.88M | 366.86M | 367.39M | 367.89M | 368.37M | 368.83M | 369.27M | 369.7M | 325.1M | 265.48M | 205.86M |
Common Stock | 2K | 2K | 2K | 2K | 2K | 2K | 2K | 2K | 2K | 2K | 2K |
Retained Earnings | -1.38B | -1.32B | -1.27B | -1.25B | -1.19B | -1.13B | -1.11B | -1.05B | -964.78M | -890.94M | -823.87M |
Comprehensive Income | -17.29M | -17.29M | -17.29M | -17.29M | -17.29M | -17.29M | -17.29M | -17.29M | -17.29M | -11.54M | -5.12M |
Shareholders Equity | -558.14M | -513.25M | -483.52M | -473.48M | -432.28M | -382.93M | -399.63M | -353.96M | -270.66M | -199.78M | -134.61M |
Total Investments | 23.85M | 29.33M | 33.15M | 27.48M | 70.02M | 97.85M | 84.83M | 10.44M | 32.32M | 17.09M | 14.97M |